DSIP Vial Size — Storage, Dosing, and Lab Use | Real Peptides

Research-grade peptides arrive as lyophilized powder in sealed glass vials, and the size you select determines far more than the quantity you receive. A 2mg DSIP vial diluted with 2mL bacteriostatic water creates a solution twice as concentrated as a 10mg vial mixed with 10mL. Which affects dosing precision, shelf life after reconstitution, and the number of injections you can draw from a single vial without introducing contamination risk. The gap between efficient peptide use and wasted product comes down to matching vial size to protocol duration and injection frequency.

We've supplied peptides to hundreds of research facilities. The most common error isn't contamination during reconstitution. It's selecting a DSIP vial size that doesn't align with study timelines, forcing researchers to either waste peptide or extend protocols beyond the 28-day post-reconstitution stability window.

What is the standard DSIP vial size for research peptide applications?

DSIP vial sizes typically range from 1mg to 10mg of lyophilized powder per sealed sterile vial. The 5mg vial is the most common format for short-term studies requiring daily injections over 14–21 days, while 10mg vials suit extended protocols or higher-dose testing. Vial size directly determines reconstitution volume, solution concentration, and post-mixing stability duration.

Yes, DSIP vial size impacts research outcomes. But not through potency differences. The peptide molecule is identical regardless of vial size. The operational difference is solution stability after reconstitution: larger vials allow for lower-concentration mixes that remain stable longer, while smaller vials force higher concentrations that degrade faster once mixed with bacteriostatic water. One critical detail most suppliers won't mention: every needle puncture through the rubber stopper increases contamination risk. A 2mg vial requiring daily draws runs through its 28-day sterility window faster than a 10mg vial with the same injection schedule. This article covers exactly how DSIP vial size affects reconstitution ratios, storage timelines, dosing accuracy, and why the cheapest per-milligram option isn't always the most cost-effective choice for your specific protocol.

How DSIP Vial Size Determines Reconstitution Protocol and Solution Concentration

The DSIP vial size you select sets the foundation for every step that follows. Reconstitution volume, final peptide concentration, dosing precision, and post-mixing stability. DSIP (Delta Sleep-Inducing Peptide) arrives as a white or off-white lyophilized powder inside a sterile glass vial sealed with a rubber stopper and aluminum crimp cap. The peptide itself is hygroscopic, meaning it absorbs moisture from air. Which is why vials are shipped under vacuum or inert gas and must remain sealed until reconstitution.

Reconstitution is the process of adding bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) to the lyophilized peptide, dissolving it into an injectable solution. The volume of bacteriostatic water you add determines the final concentration, measured in micrograms per milliliter (µg/mL) or milligrams per milliliter (mg/mL). A 5mg DSIP vial mixed with 5mL bacteriostatic water yields a 1mg/mL solution. Meaning each 0.1mL (100 units on a standard insulin syringe) contains 100µg of peptide. The same 5mg vial mixed with 2.5mL yields a 2mg/mL solution, doubling the peptide concentration per unit volume.

Why does this matter? Higher concentrations mean smaller injection volumes, which reduces tissue trauma and allows for more precise dosing when working with low-microgram protocols. But higher concentrations also increase aggregation risk. The tendency for peptide molecules to clump together in solution, reducing bioavailability and stability. DSIP's molecular weight is approximately 849 Da, and at concentrations above 2mg/mL in aqueous solution, aggregation accelerates, especially at refrigeration temperatures (2–8°C). Most published DSIP research protocols use concentrations between 0.5mg/mL and 1.5mg/mL to balance dosing precision with solution stability.

The relationship between DSIP vial size and reconstitution volume follows a predictable pattern: smaller vials (1–2mg) typically require 1–2mL bacteriostatic water to achieve usable concentrations, while larger vials (10mg) accommodate 5–10mL dilutions. A 10mg vial reconstituted with 10mL bacteriostatic water creates a 1mg/mL solution, yielding 100 doses of 100µg each. Assuming no waste, no contamination, and use within the 28-day sterility window. A 2mg vial at the same 1mg/mL concentration yields 20 doses, requiring a new vial every three weeks for daily injection protocols.

Vial size also determines draw efficiency. Each time a needle punctures the rubber stopper, microscopic rubber particles (coring) can enter the solution, and the vacuum seal weakens slightly. A 2mg DSIP vial requiring 20 draws experiences 20 puncture events; a 10mg vial with the same protocol experiences the same 20 punctures but still has 80% of its peptide remaining. The practical implication: larger vials reduce per-dose contamination exposure when protocols extend beyond two weeks.

Storage Duration and Stability Timelines for Different DSIP Vial Sizes

Unreconstituted DSIP in lyophilized form remains stable for 24–36 months when stored at −20°C, protected from light and moisture. The peptide's stability in this state is exceptional. Degradation rates at proper storage temperature are less than 2% per year based on HPLC analysis. Once you add bacteriostatic water, everything changes. The reconstituted peptide becomes vulnerable to hydrolysis (breakdown via water interaction), oxidation, and bacterial contamination despite the benzyl alcohol preservative.

The industry-standard stability window for reconstituted peptides stored at 2–8°C is 28 days. Not because the peptide fully degrades at day 29, but because sterility cannot be guaranteed beyond that point even with bacteriostatic water. Benzyl alcohol at 0.9% concentration inhibits bacterial growth, but it does not sterilize the solution. Every needle draw introduces potential contamination, and over time, bacterial load increases even under refrigeration. Published studies on reconstituted peptide stability show that DSIP retains greater than 95% potency for 21 days at 4°C, dropping to approximately 85–90% potency by day 28, and continuing to degrade thereafter.

DSIP vial size affects how you navigate this timeline. A 2mg vial used in a daily 100µg injection protocol (1mg/mL concentration, 0.1mL per dose) provides 20 doses. Exactly at the safe storage limit if injections occur daily without interruption. A 5mg vial at the same concentration provides 50 doses, which exceeds the 28-day window unless injection frequency increases to twice daily. A 10mg vial provides 100 doses, requiring either a multi-subject protocol or acceptance of peptide degradation beyond the stability window.

The solution: match DSIP vial size to protocol duration. For single-subject studies running 14–21 days with daily injections, a 2mg or 5mg vial minimizes waste. For multi-subject studies or extended timelines, a 10mg vial reduces per-dose cost but requires strict adherence to sterile technique and acceptance of declining potency in the final week. Our team has reviewed this pattern across hundreds of research orders. Facilities running tight 2-week protocols almost never order 10mg vials, while long-term metabolic studies consistently choose the largest available size despite the stability trade-off.

Temperature excursions are the silent killer of reconstituted peptides. A single temperature spike above 25°C for more than two hours can denature the peptide structure irreversibly, rendering the solution inactive. This is especially critical for DSIP vial sizes above 5mg, where the economic loss from a storage failure is significant. Refrigeration units with digital monitoring and alarm systems are non-negotiable for peptide storage. A standard household refrigerator with inconsistent cooling cycles is not adequate for research-grade peptide preservation.

Dosing Precision and Injection Volume Considerations Across DSIP Vial Sizes

Dosing precision is the ability to measure and deliver the exact intended peptide quantity per injection, and it depends on solution concentration, syringe calibration, and injection volume. Standard insulin syringes are calibrated in units, where 100 units equals 1mL. A 0.5mL (50-unit) insulin syringe allows measurement down to 1-unit increments, each representing 0.01mL of solution. At a DSIP concentration of 1mg/mL, each unit on the syringe delivers 10µg of peptide. Precise enough for most research protocols. At 2mg/mL concentration, each unit delivers 20µg, and at 0.5mg/mL concentration, each unit delivers 5µg.

The relationship between DSIP vial size and dosing precision emerges when you consider practical injection volumes. Research protocols for DSIP typically range from 25µg to 500µg per injection, depending on the endpoint being measured (sleep architecture, cortisol modulation, stress response). A 100µg dose at 1mg/mL concentration requires a 0.1mL injection. 10 units on a standard syringe, easily measured with minimal human error. The same 100µg dose at 0.5mg/mL concentration requires a 0.2mL injection. 20 units, still within the precision range of insulin syringes.

Smaller DSIP vial sizes (1–2mg) force higher concentrations if you want to avoid running out of peptide mid-protocol. A 1mg vial mixed with 1mL bacteriostatic water yields a 1mg/mL solution with only 10 doses of 100µg each. This works for pilot studies but leaves no margin for error. A single contaminated draw or measurement mistake consumes 10% of your total peptide supply. Larger vial sizes (5–10mg) allow for lower concentrations and higher total volume, creating a buffer against waste. A 10mg vial mixed with 10mL bacteriostatic water still yields 1mg/mL concentration but provides 100 doses instead of 10.

Injection volume also affects subcutaneous tissue tolerance. Volumes below 0.5mL are generally well-tolerated with minimal tissue irritation, while volumes above 1mL can cause discomfort, slower absorption, and localized inflammation. DSIP is administered subcutaneously in most research models, targeting adipose tissue for gradual systemic absorption. A 500µg dose at 0.5mg/mL concentration requires a 1mL injection. The upper limit of comfortable subcutaneous volume. The same dose at 1mg/mL concentration requires only 0.5mL, improving subject tolerance and absorption consistency.

DSIP vial size affects how you balance these variables. If your protocol requires high per-dose quantities (300–500µg), smaller vials force impractically high concentrations or uncomfortably large injection volumes. A 2mg vial cannot support a 500µg daily dose for more than four days at any reasonable concentration. A 10mg vial, by contrast, supports the same dose for 20 days at a comfortable 1mg/mL concentration and 0.5mL injection volume. Cost per milligram favors bulk purchasing, but only if the protocol can consume the peptide within the post-reconstitution stability window.

DSIP Vial Size: Format Comparison for Research Applications

Choosing the right DSIP vial size depends on protocol duration, injection frequency, dosing precision requirements, and cost efficiency. The table below compares the three most common vial formats across the variables that matter most for research planning.

The 5mg DSIP vial size represents the sweet spot for most research applications. Enough peptide to complete a standard 3–4 week protocol without running short, while staying within the 28-day post-reconstitution stability window. Facilities ordering 2mg vials typically do so for exploratory work where the protocol may change mid-study, and committing to a larger vial risks waste. Facilities ordering 10mg vials are running either multi-subject parallel studies or extended timelines where per-milligram cost becomes the dominant variable.

Key Takeaways

• DSIP vial sizes range from 1mg to 10mg lyophilized powder, with 5mg being the most common format for single-subject daily injection protocols lasting 3–4 weeks.
• Reconstituted DSIP retains greater than 95% potency for 21 days at 2–8°C and declines to approximately 85–90% potency by day 28, making vial size selection critical for minimizing waste.
• A 10mg DSIP vial reconstituted with 10mL bacteriostatic water yields 100 doses of 100µg each at 1mg/mL concentration, while a 2mg vial yields only 20 doses at the same concentration.
• Higher peptide concentrations (above 2mg/mL) increase aggregation risk and reduce solution stability, making larger vial sizes with dilute mixes preferable for extended protocols.
• Every needle puncture through the vial stopper increases contamination risk. Larger DSIP vial sizes reduce per-dose exposure when protocols require frequent draws over multiple weeks.
• Cost per milligram decreases with larger vial sizes, but only facilities with protocols long enough to consume the peptide within 28 days post-reconstitution should order 10mg vials.

What If: DSIP Vial Size Scenarios

What If I Accidentally Reconstitute a 10mg DSIP Vial with the Wrong Volume of Bacteriostatic Water?

Recalculate your concentration immediately using the formula: concentration (mg/mL) = total peptide mass (mg) ÷ total volume added (mL). If you added 5mL instead of 10mL to a 10mg vial, your concentration is 2mg/mL instead of 1mg/mL. Meaning each 0.1mL injection now delivers 200µg instead of 100µg. Adjust your draw volume proportionally to maintain the intended dose, or discard the solution and reconstitute a new vial if precision is critical to your protocol. Diluting an already-reconstituted solution by adding more bacteriostatic water is not recommended. It introduces additional contamination risk and dilutes the benzyl alcohol preservative below effective concentration.

What If My DSIP Vial Size Runs Out Before My Protocol Ends?

Order a replacement vial immediately and reconstitute it at the same concentration as the depleted vial to maintain dosing consistency. If you're mid-protocol and cannot source an identical DSIP vial size, calculate the concentration needed to match your original dosing regimen. For example, if you were using a 5mg vial at 1mg/mL and only a 2mg vial is available, reconstitute the 2mg vial with 2mL to maintain the 1mg/mL concentration. Document the vial change in your protocol notes, as switching mid-study introduces a variable that may affect reproducibility. Avoid combining peptide from multiple vials into a single container. This violates sterile technique and increases contamination risk exponentially.

What If I'm Running a Multi-Subject Study and Need to Determine the Right DSIP Vial Size?

Calculate total peptide consumption across all subjects and timelines, then add a 15–20% buffer for waste, measurement error, and potential protocol extensions. For example, a study with 5 subjects receiving 100µg daily for 21 days requires 10.5mg total peptide (5 subjects × 100µg × 21 days = 10,500µg = 10.5mg). Order two 10mg vials rather than five 2mg vials. The per-milligram cost is lower, and you'll have surplus peptide if any subject requires extended dosing. Reconstitute only one vial at the start, keeping the second vial in lyophilized form at −20°C until needed. This approach minimizes waste while ensuring peptide availability throughout the study without forcing concentration changes mid-protocol.

The Practical Truth About DSIP Vial Size Selection

Here's the honest answer: the DSIP vial size that seems cheapest upfront is almost never the most cost-effective choice when you account for waste, stability windows, and dosing consistency. A 10mg vial costs less per milligram than a 2mg vial, but if your protocol only requires 3mg total and the remaining 7mg degrades past the 28-day window, you've paid for peptide you cannot use. Cost efficiency is not about the lowest per-unit price. It's about the lowest cost per usable dose delivered within the stability timeline.

The bottom line: match DSIP vial size to your protocol duration first, cost second. A 5mg vial fits most standard research timelines (14–28 days, daily injections) without forcing you to either rush through a protocol or accept degraded peptide in the final week. Facilities that consistently order the largest available vial size to